355 related articles for article (PubMed ID: 20555361)
1. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
2. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
3. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
5. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
6. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
7. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
9. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
10. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
Lü SQ; Yang JM; Huang CM; Xu XQ; Zhou H; Song NX; Wang JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):869-73. PubMed ID: 21867604
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Rückrich T; Kraus M; Gogel J; Beck A; Ovaa H; Verdoes M; Overkleeft HS; Kalbacher H; Driessen C
Leukemia; 2009 Jun; 23(6):1098-105. PubMed ID: 19225532
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
14. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
16. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
17. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
18. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
[TBL] [Abstract][Full Text] [Related]
19. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
20. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Gu H; Chen X; Gao G; Dong H
Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]